Detection and treatment of CD30+ cancers
US-11366118-B2 · Jun 21, 2022 · US
Detection and treatment of CD30+ cancers
US12590968B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12590968-B2 |
| Application number | US-202217747591-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 18, 2022 |
| Priority date | Feb 10, 2012 |
| Publication date | Mar 31, 2026 |
| Grant date | Mar 31, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30 + cancers.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of treating a CD30 positive melanoma, comprising administering an effective regimen of brentuximab vedotin to a patient having the melanoma, wherein at least 10% of the malignant or atypical cells in a sample of the melanoma have been identified as expressing CD30. 2 . The method of claim 1 , wherein at least 50% of the malignant or atypical cells in the sample have been identified as expressing CD30. 3 . The method of claim 1 , wherein CD30 expression is detected in the cell membrane and/or Golgi of the malignant or atypical cells. 4 . The method of claim 3 , wherein CD30 expression is detected after fixing the malignant or atypical cells with formalin and embedding in paraffin.
Assignees
Inventors
Classifications
against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title
the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title
NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95 · CPC title
Antineoplastic agents · CPC title
- G01N33/5759Primary
involving compounds localised on the membrane of tumour or cancer cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12590968B2 cover?
- The application provides methods of diagnosis, prognosis, prophylaxis and treatment of CD30 + cancers.
- Who is the assignee on this patent?
- Seagen Inc
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5759. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Mar 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).